Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Behrens

Showing results (341-350 of 363) with videos related to

Pageof 37
Sort By:
Immunotherapy|June 18, 2025
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summaryShanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Dysregulated STAT3 signaling and T cell immunometabolic dysfunction define a targetable, high mortality subphenotype of critically ill childrenRobert B Lindell, Samir Sayed, Jose S Campos, et al.
Annals of the Rheumatic Diseases|July 24, 2023
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)Bita Shakoory, Ashley Geerlinks, Marta Wilejto, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 9, 2024
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review StudyShanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 24, 2023
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)Bita Shakoory, Ashley Geerlinks, Marta Wilejto, et al.
Science Translational Medicine|November 15, 2019
A heat-stable microparticle platform for oral micronutrient deliveryAaron C Anselmo, Xian Xu, Simone Buerkli, et al.
Pediatric Blood & Cancer|September 5, 2020
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndromeCaroline Diorio, Elizabeth M Anderson, Kevin O McNerney, et al.
BMC Medical Genetics|March 24, 2016
Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibilityTerri H Finkel, Jin Li, Zhi Wei, et al.
Hepatology Communications|April 1, 2026
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotypeTamir Diamond, Catherine A Chapin, Caroline J Diorio, et al.
RMD Open|February 6, 2016
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritisAngelo Ravelli, Francesca Minoia, Sergio Davì, et al.
Pageof 37

Showing results (341-350 of 363) with videos related to

Sort By:
Pageof 37
Immunotherapy|June 18, 2025
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summaryShanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
Dysregulated STAT3 signaling and T cell immunometabolic dysfunction define a targetable, high mortality subphenotype of critically ill childrenRobert B Lindell, Samir Sayed, Jose S Campos, et al.
Annals of the Rheumatic Diseases|July 24, 2023
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)Bita Shakoory, Ashley Geerlinks, Marta Wilejto, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 9, 2024
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review StudyShanmuganathan Chandrakasan, Carl E Allen, Deepika Bhatla, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 24, 2023
The 2022 EULAR/ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS)Bita Shakoory, Ashley Geerlinks, Marta Wilejto, et al.
Science Translational Medicine|November 15, 2019
A heat-stable microparticle platform for oral micronutrient deliveryAaron C Anselmo, Xian Xu, Simone Buerkli, et al.
Pediatric Blood & Cancer|September 5, 2020
Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndromeCaroline Diorio, Elizabeth M Anderson, Kevin O McNerney, et al.
BMC Medical Genetics|March 24, 2016
Variants in CXCR4 associate with juvenile idiopathic arthritis susceptibilityTerri H Finkel, Jin Li, Zhi Wei, et al.
Hepatology Communications|April 1, 2026
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotypeTamir Diamond, Catherine A Chapin, Caroline J Diorio, et al.
RMD Open|February 6, 2016
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritisAngelo Ravelli, Francesca Minoia, Sergio Davì, et al.
Pageof 37